Abstract: Objective To observe the efficacy of denosumab combined with percutaneous kyphoplasty (PKP) in the treatment of osteoporotic vertebral compressed fracture (OVCF) in the elderly women. Methods A total of 102 elderly female patients with thoracolumbar vertebral compressed fracture who underwent PKP were divided into control group and treatment group according to whether they received denosumab treatment. The control group received oral calcium carbonate and vitamin D3 tablets and alfacalcidol soft capsules, while the treatment group received denosumab in addition to the control group’s dosage regimen. The scores of Visual Analogue Scale (VAS)and Oswestry Disability Index (ODI) were used to evaluate pain improvement and the effect of the patients before surgery and 3 days, 6 and 12 months after treatment. The incidence rate of adjacent vertebral refracture and changes in bone mineral density at 1-year followup were compared between the two groups. Results After 6 and 12 months of treatment, VAS and ODI scores of the control group increased, and the ODI scores of the treatment group decreased compared with those 3 days after treatment, and there were significant differences between the two groups (P＜0.05). After 12 months of treatment, the bone mineral density of the treatment group was significantly higher than that before treatment and that of the control group (P＜0.05); The adjacent vertebral refracture rate in the treatment group was significantly lower than that in the control group (P＜0.05). Conclusions Denosumab combined with PKP can prominently improve the clinical efficacy of OVCF treatment, effectively alleviate clinical symptoms, increase bone mineral density, reduce the risk of adjacent vertebral refracture after surgery and improve long-term prognosis of the elderly women patients.

Key words: osteoporotic vertebral compressed fracture, denosumab, percutaneous kyphoplasty